Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.84 |
| ▸ | JAK1 | P23458 | 3/20 | 0.69 |
| ▸ | AXL | P30530 | 2/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.67 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.67 |
| ▸ | MERTK | Q12866 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14377767 | 1.00 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL21412834 | 1.00 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL14376756 | 1.00 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL16532750 | 0.95 | JAK2 (0.80) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22449882 | 0.95 | JAK2 (0.80) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22622522 | 0.94 | JAK2 (0.79) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22449884 | 0.94 | JAK2 (0.79) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL14331940 | 0.94 | JAK2 (0.83) | JAK2JAK1AXL | |
| SCHEMBL14376754 | 0.91 | JAK2 (1.00) | JAK2JAK1AXL | |
| SCHEMBL15801115 | 0.91 | JAK2 (1.00) | JAK2JAK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565229-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | Incyte Corporation (US) | 2025-06-11 | — | — | EP | claimed |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION | 2024-02-22 | — | — | US | claimed |
| WO-2024030600-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION (US) | 2024-02-08 | — | — | WO | claimed |
| EP-4274578-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | Incyte Corporation (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | claimed |
| US-20260021096-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORPORATION (US) | 2026-01-22 | — | — | US | disclosed |
| US-12498382-B2 | Biomarkers for vitiligo | INCYTE CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250367202-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250325664-A1 | COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-12360120-B2 | Biomarkers for graft-versus-host disease | INCYTE CORPORATION (US) | 2025-07-15 | — | — | US | disclosed |
| US-12336998-B2 | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | INCYTE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4570321-A2 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | Incyte Corporation (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20220202834-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORPORATION | 2022-06-30 | — | — | US | disclosed |
| US-11372003-B2 | Biomarkers for graft-versus-host disease | INCYTE CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220175731-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | INCYTE CORPORATION | 2022-06-09 | — | — | US | disclosed |
| US-20220177491-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2022-06-09 | — | — | US | disclosed |
| US-11324749-B2 | Combination therapy for treatment of hematological diseases | INCYTE CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-11304949-B2 | Treatment of hidradenitis suppurativa using JAK inhibitors | INCYTE CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220040187-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | INCYTE CORPORATION | 2022-02-10 | — | — | US | disclosed |
| US-20220024934-A1 | SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR | INCYTE CORPORATION | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11372003-B2 | Biomarkers for graft-versus-host disease | CD74, HLA-DRB1, TSG101 | JAK2 26/4885JAK1 5/4885AXL 3610/4885 |
| US-12336998-B2 | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | JAK1, IRAK1, STAT3 | JAK2 8/4885JAK1 1/4885AXL 508/4885 |
| US-11304949-B2 | Treatment of hidradenitis suppurativa using JAK inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885AXL 2137/4885 |
| US-12360120-B2 | Biomarkers for graft-versus-host disease | CD74, HLA-DRB1, TSG101 | JAK2 38/4885JAK1 7/4885AXL 3882/4885 |
| US-12498382-B2 | Biomarkers for vitiligo | TSG101, JAK3, IFNG | JAK2 13/4885JAK1 5/4885AXL 2777/4885 |
| US-20260021096-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885AXL 274/4885 |
| US-20250325664-A1 | COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR | JAK1, CSF3R, JAK3 | JAK2 5/4885JAK1 1/4885AXL 1049/4885 |
| US-20220040187-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | JAK1, IRAK1, STAT3 | JAK2 8/4885JAK1 1/4885AXL 508/4885 |
| US-20220024934-A1 | SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR | PIK3CD, PIK3CA, PIK3CG | JAK2 75/4885JAK1 43/4885AXL 486/4885 |
| US-20220175731-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885AXL 924/4885 |
| US-11324749-B2 | Combination therapy for treatment of hematological diseases | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885AXL 1288/4885 |
| US-20220202834-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | JAK3, IL23R, JAK1 | JAK2 5/4885JAK1 3/4885AXL 2825/4885 |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885AXL 559/4885 |
| US-20250367202-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | JAK1, IRAK1, STAT3 | JAK2 8/4885JAK1 1/4885AXL 508/4885 |
| US-20220177491-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R1 | JAK2 39/4885JAK1 88/4885AXL 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.